Etoposide phosphate
- PDF / 150,968 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 79 Downloads / 188 Views
1 S
Immediate hypersensitivity reaction due to dextran excipient: case report A 66-year-old man developed immediate hypersensitivity reaction during treatment with etoposide phosphate containing dextran [dextran 40] as an excipient for enteropathy-associated T-cell lymphoma. The man was diagnosed with enteropathy-associated T-cell lymphoma and received 4 cycles of BV-CHP regimen consisting of doxorubicin, brentuximab vedotin, and cyclophosphamide that was followed by methotrexate. Along with this, he also received an infusion of etoposide phosphate 360 mg containing dextran [dextran 40] as an excipient. Immediately, following the initiation of etoposide phosphate, he developed severe hypersensitivity reaction. He was admitted to the ICU. The hypersensitivity reaction manifested as anaphylactic shock with low blood pressure, rash, oxygen desaturation, and tachycardia. His chest, cardiovascular and neurological tests were normal. The man was administered adrenalin and hydrocortisone hemisuccinate. Thereafter, his symptoms gradually improved. Eventually, he completed the cycle of methotrexate with etoposide base formulation and received BEAM regimen without any complication. Based on the findings, the hypersensitivity reaction was considered secondary to dextran, which is an excipient of etoposide phosphate. Cotteret C, et al. Severe hypersensitivity reaction to etoposide phosphate: A case report. Clinical Case Reports : 6 Aug 2020. Available from: URL: http://doi.org/10.1002/ 803498828 ccr3.2732
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
